tilsotolimod + ipilimumab

Tilsotolimod + ipilimumab is a combination therapy investigated primarily for the treatment of advanced melanoma that is refractory to anti–PD-1 therapy. Tilsotolimod (IMO-2125) is a synthetic oligonucleotide and Toll-like receptor 9 (TLR9) agonist administered via intratumoral injection, designed to activate dendritic cells and induce a local type I interferon response, thereby promoting antigen presentation and T-cell activation. Ipilimumab is a monoclonal antibody targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4), functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor activity. The rationale for combining these agents is that tilsotolimod’s activation of innate immunity may potentiate the adaptive immune response triggered by CTLA4 inhibition with ipilimumab. Clinical trials have shown that while this combination can induce immune responses in some patients, large phase III studies did not demonstrate improved objective response rates or overall survival compared to ipilimumab alone in anti–PD-1-refractory advanced melanoma[1][2][3][5][7]. The development program has included other tumor types such as microsatellite stable colorectal cancer[6].